IL-FOURKITES
14.3.2024 12:31:31 CET | Business Wire | Press release
Leading real-time supply chain visibility provider FourKites® today announced the promotion of Priya Rajagopalan to President of Product, Technology and Operations, as well as the appointment of Ron Richardson as Chief Revenue Officer (CRO). These appointments underscore FourKites’ focus on rapid growth and innovation, with an eye toward solving customers’ most pressing needs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240314808596/en/
FourKites promotes Priya Rajagopalan to President of Product, Technology and Operations and appoints Ron Richardson as Chief Revenue Officer to drive industry adoption and accelerate customer value (Photo: Business Wire)
Priya Rajagopalan leads FourKites’ Product, Engineering and Customer functions, with the goal of aligning customer needs and the company’s innovation engine to drive maximum customer value. Rajagopalan joined FourKites seven years ago as Chief Product Officer, bringing with her a wealth of experience in product management from various startups and public companies. Currently, Rajagopalan also serves on the Board of Directors of Brambles (ASX: BXB), the supply-chain logistics company operating across 60 countries through the CHEP brand. A testament to her industry contributions, she has been named an SDCE Pros to Know, and one of The Software Report’s Top 25 Software Product Executives.
Under Rajagopalan’s direction, FourKites has rolled out a number of industry-first product innovations, including real-time facility manager Dynamic Yard; end-to-end international ocean shipments tracker Dynamic Ocean; generative AI assistant Fin AI; patented AI-powered ETA forecaster Smart Forecasted Arrival; universal appointment scheduler Appointment Manager; and others.
“FourKites defined and created the supply chain visibility category, and innovating with customers has been, and continues to be part of our company’s DNA,” said Rajagopalan. “This alignment allows us to innovate and execute at even greater speed to ensure successful deployment and adoption across our customers."
Ron Richardson returns to FourKites as CRO, where he leads Sales, Partners and Alliances to drive FourKites’ global momentum. Ron recently served as CRO at OneRail, a solution that has redefined last-mile delivery, as well as CRO at Turvo, where he helped scale the company revenue and position it for a successful exit. Previously, Richardson was one of FourKites’ first employees, where he was instrumental in creating the real-time transportation visibility platform (RTTVP) category, building the business and closing some of the company’s earliest customer deals, including Coca-Cola, Nestlé and many more.
“I am thrilled to come back home to FourKites — returning to the market-leading company and the industry category I helped pioneer,” said Richardson. “I look forward to building on the momentum the team and I jump-started in the early years, driving growth and success among our Fortune 500 enterprise customers who continue to see massive value with the FourKites platform.”
“These promotions reflect our confidence in Priya’s and Ron’s leadership and their ability to propel FourKites to even greater heights,” said FourKites founder and CEO Mathew Elenjickal. “Priya’s unique blend of deep technical knowledge, innate leadership skills and collaborative approach has earned her admiration from industry leaders, investors and customers alike. Likewise, Ron brings deep industry experience, a strong track record as a successful CRO and, most importantly, vast knowledge of our existing customers and ecosystem. Under their leadership, we will continue to innovate, grow and solidify our position as the de-facto leader in the supply chain visibility space.”
About FourKites
Leading global supply chain visibility platform FourKites® empowers business leaders with comprehensive visibility into transportation, yards, warehouses, stores and beyond. Tracking more than 3.2 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitize their end-to-end supply chains. More than 1,500 of the world’s most recognized brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240314808596/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
